Smarq Human papillomavirus (HPV) type 16 and 18 viral genomes are frequently detected in cervical and penile cancer biopsies. Although this strongly suggests a prominent role for HPV infection in the development of genital cancer, other genetic or environmental factors are also involved. Genital cancer is postulated to result from loss of cellular control functions, which leads to an unregulated expression of HPV oncogenic proteins. In our study, we determined the trans-activating properties of nuclear proto-oncogene proteins c-Fos, c-Jun and c-Myc on P97 enhancer/promoter activity of HPV16. Using a CAT-reporter construct containing the HPV16 enhancer/promoter element, we investigated the trans-activating effects of c-Fos, c-Jun, c-Myc, and E2 in cervical HT-3 cells. c-Fos and c-Jun overexpression resulted in a 3.3-and 3.1-fold up-regulation of CAT activity. Only 2-fold induction was determined by co-transfection with c-myc and the viral transcription factor E2. Based on these findings, we investigated the expression of HPV DNA (16 and 18) as well as nuclear proto-oncogenes (c-fos, c-jun and c-myc) in nine cervical cancers by in situ hybridisation. In six out of nine carcinomas, HPV16 and/or HPV18 DNA was detectable. All tumours showed an intense and homogeneous expression of c-fos and c-jun mRNA, while the signal for c-myc was detectable only in four specimens. These data suggest that deregulation of nuclear proto-oncogene expression may contribute to an overexpression of HPV-derived oncogenic proteins (E6 and E7), which is generally hypothesised to be an important step in the malignant transformation of HPV-associated tumours.
Certain types of human papillomaviruses have been found to be highly associated with carcinomas of the human uterine cervix. The oncogenic human papillomaviruses, particularly HPV16 and HPV18, have been suggested to play an important role in carcinogenesis of this type of neoplasia (zur Hausen and Schneider, 1987) . HPV infections alone are most likely insufficient for malignant transformation since infection with high-risk HPV types is quite common (Young et al., 1989) , and only a small proportion of patients eventually develop cervical cancer after long periods of latency (zur Hausen, 1986 ). These observations suggest that additional factors are required in the multistep process of tumorigenesis.
In recent years, there has been ongoing controversy about the role of (proto-)oncogenes in the pathogenesis of cervical neoplasms. Elevated levels, amplification and/or rearrangement of the c-myc oncogene have been reported in carcinomas of the uterine cervix (Ocadiz et al., 1987; Riou et al., 1987; Bourhis et al., 1990; Cromme et al., 1993) , but these findings have not been confirmed by others (Hendy-Ibbs et al., 1985; Choo et al., 1989; Hughes et al., 1989) . In vitro studies have, however, clearly shown that those HPV types which are most commonly found in carcinomas are able to cooperate with activated oncogenes (ras, myc and fos) to produce cells with tumorigenic characteristics (Matlashewski et al., 1987; Storey et al., 1988; Bedell et al., 1989; Crook et al., 1989) . In addition, in some cervical carcinomas and cervical carcinoma-derived cell lines, integration of papillomavirus sequences has been found near cellular oncogenes, suggesting that at least in some genital tumours Distel and Spiegelman, 1990; Vogt and Bos, 1990; Angel and Karin, 1991) . Papillomaviruses with mucosal tropism including HPV16 contain up to three binding sites for AP-1 in their upstream regulatory region (Chong et al., 1990) , which have been revealed to be functionally active (Cripe et al., 1990) .
The role of c-myc in HPV-associated oncogenesis is currently under discussion. Recently, it has been demonstrated that c-Myc binds DNA specifically (Blackwell et al., 1990; Prendergast and Zif, 1991) . However, the set of genes regulated by this nuclear proto-oncogene is unknown, indicating that the direct biochemical actions of the c-Myc protein remain unclear.
Since nuclear proto-oncogenes with potential gene-regulating activity might be involved in human papillomavirusassociated carcinogenesis, we have investigated the transactivating properties of c-Fos, c-Jun and c-Myc on the P97 promoter, which controls the expression of E6 and E7 oncoproteins in HPV16. Using in situ hybridisation, we compared these in vitro results with proto-oncogene expression patterns m cervical carcinomas.
Materials and mnetbod
Cell culture HT-3 cells (kindly provided by P.G. Fuchs, Erlangen, Germany) derived from a cervical carcinoma (Fogh and Trempe, 1975) were cultured in RPMI-1640 medium (Gibco Laboratories) containing 10% fetal calf serum (FCS), supplemented with penicillin (l00Uml') and streptomycin (l00jigmlI').
HT-3 cells are free of endogenous papillomavirus genomes (Yee et al., 1985) .
Construction ofplasmids
The HPV-16 DNA cloned into pBR322 has been described (Durst et al., 1983 ) and was kindly provided by H zur Hausen of the Deutsches Krebsforschungszentrum, Heidelberg, Germany. A DNA fragment corresponding to the long control region (LCR) of HPV16 (5'EcoRI, 3'Sau96I, nucleotides 7453-112) was cleaved from the HPV16 genome and cloned by blunt end ligation into the pCAT-basic plasmid (Promega, Heidelberg, Germany) at the XbaI site, generating the pHPV16LCR (Figure 1 ). Insert-containing clones were identified using restriction analysis.
CAT-reporter plasmids pCMV-CAT, pRSV-CAT and pSVE-CAT containing virus enhancer/promoter sequences are described elsewhere (Artuc et al., 1993) . Several expression plasmids for proto-oncogenes and HPV16-derived E2 were used in this study and have been described previously: HPV16-denrved E2 expression vector p859 and precursor plasmid p77.01 (Phelps and Howley, 1987) (Ellis et al., 1986) .
For in situ hybnrdisation (ISH), specific probes were generated using a U937 cDNA library. According to standard procedures, polymerase chain reactions were performed to generate specific DNA fragments . For amplification, primers for c-fos (5'-GCCGTCTC-CAGTGCCAACI-ICATlTCCC-3'; 5'-CTTCACACCGCCA-GCCCTGGAGTAAGC-3') generated a 180 bp DNA fragment, for c-mrnc (5'-AATGTCAAGAGGCGAACACACAA-CGTC-3': 5'-TITAAGGATAACTACCITrGGGGGCCTIT-3') a 135 bp fragment and for c-jun (5'-CTCACCTCGCCCGA-CGTGGGGCTGCTC-3'; 5'-TTCGGCCAGGGCGCGCAC-GAAGCCCTC-3') a 180 bp fragment. Immunohistochemistry was performed according to the protocol of Boehringer Mannheim. Briefly, slides were washed in buffer 1 (100 mM maleic acid, 100 mM sodium chlonrde, 0.3% Triton X pH 7.5) for 2 min. Sections were preincubated in 1% Blocking Reagent (Boehringer Mannheim, Germany) containing 10% normal sheep serum for 1 h at room temperature. Thereafter, 200 gi of the anti-digoxigenin conjugate (1:500 in buffer 1 containing 10% normal sheep serum) was placed on the slides for 3 h at room temperature. Washing steps were repeated, 5 min in buffer 1 and 5 min in a buffer containing 100 mM Tris-HCl, 100 mM sodium chloride, 50 mM magnesium chloride (pH 9.5), followed by incubation of the sections in colour solution (per ml: 4.5 gl of 4-nitroblue tetrazolium, 4.5 glI of 5-bromo-4-chloro-3-indolylphosphate and 3.8 mg of levamisole) at room temperature in the dark. Sixteen hours later, the reaction was stopped by washing the slides in 10 mM Tris-HCl, 1 mM EDTA pH 8.0 for 5 min. Finally, the sections were mounted in Kaiser's glycerin-gelatin without counterstain.
To estimate the amount of specific mRNA. expression in the cells and tissues, the signal intensity of the colour was compared after 16 h of immunological detection (-, no signal; +, weak signal; + +, moderate signal; + + +, strong signal).
Results
Activities of various eukaryotic promoters in HT-3 cells Sufficient expression of trans-activating proteins as well as a sufficient promoter activity of the reporter gene are prerequisites for trans-activation experiments. Furthermore, since it has been shown that eukaryotic promoter activities show cell type-dependent activity (Artuc et al., 1993), we determined the activities of various promoters including the human papillomavirus type 16, the cytomegalovirus (CMV), simian virus (SV40) and Rous sarcoma virus (RSV) promoters in HT-3 cells. As shown in Figure 2 , all plasmids containing promoter and enhancer sequences were active in HT-3 cells. The CMV promoter displayed the strongest CAT activity (98.5%), followed by RSV (24.1%) and SV40 early promoter (14.2%). The HPV16 (pHPV16LCR) promoter had a basal activity (4.6%) which was one-fifth of that of the RSV promoter. The promoterless plasmid and the SV40 promoter plasmid without enhancer region showed identical low background CAT activities (Table I) .
Trans-activation of nuclear proto-oncogenes and E2
In order to investigate the trans-activating properties of nuclear proto-oncogenes on the HPV16 P97 enhancer/ promoter, we co-transfected the HPV16 reporter plasmid with plasmids expressing the c-Fos, c-Jun, c-Myc and HPV16-E2 proteins in HT-3 cells (Figure 3 , Table II ). CAT activity was stimulated 3.1-and 3.3-fold by c-Jun and c-Fos respectively. A weak but reproducible stimulation was detectable by co-transfecting the c-myc (1.9-fold) and E2 plasmids (2.1-fold). As shown in Figure 3 , co-transfection of the control plasmids pECE or p77.01 gave only minor background activity. These data indicate that overexpression of nuclear proto-oncogenes in HT-3 cells resulted in a clear induction of the HPV16 P97 promoter activity. In order to study the c-onc and HPV expression in cervical carcinomas, we performed in situ hybridisation in HT-3 cells and nine invasive epidermoid (squamous cell) carcinomas of the cervix. The HPV-negative HT-3 cells showed no or only weak expression of c-myc and c-fos mRNA, while the c-jun sigal appeared moderate (Table HII) . Six of nine cervical tissues showed HPV16/18 DNA. In contrast to the normalappearing cervical mucosa or stroma (Figure 4 ), c-fos and c-jun mRNA were expressed in most tumours at high levels. Comparing the signal intensity of c-fos and c-jun, both protooncogenes were expressed in most neoplasms at similar levels. Differences in patterns of proto-oncogene expression between HPV16/18-positive and HPV16/18-negative cervical carcinomas were not detectable. Four of nine tumour specimens expressed detectable amounts of c-myc mRNA at low levels.
Disusssio
In recent years, great interest has been focused on transcriptional regulation of human papillomaviruses since this might help to understand the factors involved in the multistep process of carcinogenesis (Cripe et al., 1990; Chong et al., 1990 Chong et al., , 1991 . In the present study, we have investigated the transcriptional regulation of different nuclear proto-oncogenes on the P97 enhancer/promoter using the cervical carcinoma cell line HT-3. This cervical carcinoma cell line is free of endogenous papillomavirus gene products and shows only a moderate expression of c-onc (Table III) (Boshart et al., 1985) . The activity of the HPV16 enhancer/promoter was about one-third that of the pSVE-CAT (4.6% vs 14.2%), indicating that the P97 enhancer/promoter is about 5-to 30-fold more active in cervical HT-3 cells than in primary human keratinocytes (Romanczuk et al., 1990) . After co-transfection with c-fos or c-jun expression plasmids, the transcriptional activity in HT-3 cells was stimulated about 3.3-or 3.1-fold respectively. This is in agreement with data described by Cripe et al. (1990) , who found a 7.9-fold increased transcriptional activation after co-transfection of a P97 reporter plasmid with c-jun. In contrast to our study, transfection experiments were performed in undifferentiated mouse F9 teratocarcinoma cells, and the investigators used the P97 reporter plasmid, which contains an LCR core sequence of only 88 nt. It has been reported that shortening of enhancer/promoter regions in reporter plasmids may result in a stronger trans-activation (Zobel et al., 1992; Ku et al., 1993) , which could be the reason for the stronger trans-activation observed by Cripe et al. (1990) .
Infection of keratinocytes with consecutive integration of the HPV genome is normally not associated with fragmentation of the HPV enhancer/promoter region. Therefore, we investigated the trans-activating properties with the HPV16 regulative sequence without truncation in accordance with the situation in vivo.
c-Fos and c-Jun are the major components of the transcription factor AP-1 (Angel and Karin, 1991) . It has been reported that, in contrast to c-Fos, c-Jun proteins are able to form homodimers with DNA-binding properties (for review see Distel and Spiegelman, 1990; Angel and Karin, 1991) . However, c-Fos-c-Jun heterodimers have a higher DNAbinding activity than the c-Jun homodimers. In HT-3 cells, the endogenous c-jun mRNA level exceeded those of c-fos (Table HI) , suggesting that the induced overexpression of c-Jun might have led to homodimerisation and a consecutive trans-activation of the P97 enhancer/promoter. In agreement with analogous studies which displayed trans-activating properties of HPVl6-derived E2 on heterologous and homologous reporter plasmids (Cripe et al., 1987; Phelps and Howley, 1987) , we observed a weak trans-activation of the P97 promoter after p859 co-transfection (Table  II) , resulting in a viral E2 protein expression.
In contrast to AP-1 and E2, no potential sequence-specific DNA binding sites for the c-Myc protein are detectable on the P97 enhancer/promoter (Figure 1 ). Since c-Myc showed activating properties on the HPV16 promoter (1.9-fold), we suggest that this effect might be explained by indirect mechanisms which have been demonstrated to be independent from trans-activation (Prendergast and Cole, 1989) .
To determine the relevance of the observed c-Fos-, c-Junand c-Myc-dependent up-regulation of the HPV16 promoter, we performed in situ hybridisation studies in nine invasive cervical carcinomas. In contrast to normal-appearing cervical mucosa, all tumours showed a strong expression of c-fos and c-jun. In agreement with other studies investigating cervical carcinomas by Northern blot technique and histochemically (Bourhis et al., 1990; Cromme et al., 1993) , expression of c-myc was detectable only in less than 50% of the carcinomas investigated.
Recently, c-fos and c-jun expression was investigated in normal epidermis (Basset-Seguin et al., 1991) . It has been suggested that in those tissues, c-fos and c-jun transcripts are preferentially located in basal or suprabasal normal keratinocytes and that expression of these proto-oncogenes is linked to differentiation rather than to proliferation (BassetSeguin et al., 1994; Nurnberg et al., 1994) . In malignant cells of squamous cervical epithelium, however, c-fos and c-jun expression has been found to be distributed in a homogeneous pattern throughout the epithelium (Figure 4) , indicating alterations in c-fos and c-jun gene expression.
In conclusion, our data indicate that overexpression of proto-oncogenes such as c-fos, c-jun and c-myc results in an activation of the P97 promoter in vitro and might consecutively, as observed in vivo, up-mgulate the expression of oncogenic viral proteins. Therefore, deregulation of proto-P --m-ad HFYl 
